【859】2024 SABCS会议预告｜12月11日有哪些精彩看点？

地点和时间：Room 221ABC，12月11日 7:00 – 8:30 am

主持人：David Rimm, Yale University

PS1-01: Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with the Neoadjuvant KEYNOTE-522 Regimen.

Riya Albert, UT Southwestern Medical Center, Dallas, Texas

PS1-02: Impact of racial differences in circulating blood components and stromal tumor-infiltrating lymphocytes (sTILs) on outcomes in triple negative breast cancer (TNBC).

Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas

PS1-03: 基于三级淋巴结构预测HER2阳性乳腺癌患者新辅助治疗的疗效和预后

Prediction of Prognosis and Efficacy of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients Based on Tertiary Lymphoid Structures.

张克兢 中南大学湘雅医院

PS1-04: Tumor-infiltrating lymphocytes (TILs) and response to neoadjuvant chemotherapy in young patients with breast cancer.

Megan Tesch, Dana-Farber Cancer Institute, Boston, Massachusetts

PS1-05: Genomic characteristics related to histology-based immune features in breast cancer.

Yoon Jin Cha, Yonsei University, Seoul, South Korea

PS1-06: Intratumor tumor-infiltrating lymphocytes (iTILs) and spatial distribution pattern of stromal TILs (sTILs) evaluated by HALO AI are prognostic indicators of triple-negative breast cancer.

Makiko Fukumura-Koga, National Defense Medical College, Tokorozawa, Japan

PS1-07: Al-Derived Tumor-Infiltrating Lymphocytes Enhance the Model with Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Predicting Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.

Xiaoxi Pan, Institute of Cancer Research, London, United Kingdom

PS1-08: Deciphering the Tumor-Immune Landscape and Mechanisms of Response and Resistance to Neoadjuvant Therapy in Early-Stage Breast Cancer Using Single-Cell RNA Sequencing.

Marcela Carausu, Institut Jules Bordet in Brussels, Belgium

• 7:30-7:45 Discussant (PS1-01, PS1-02, PS1-03, PS1-04)

乳腺癌患者和亚型

The Patient and Subtype of Breast Cancer

Frederique Penault Llorca, University of Clermont-Ferrand, Clermont-Ferrand, France

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS1-05, PS1-06, PS1-07, PS1-08)

空间和细胞排列

Spatial and Cellular Arrangements

Theo Foukakis, Karolinska Institutet, Solina, Sweden

地点和时间：Stars at Night 1-2，12月11日 7:00 – 8:30 am

主持人：Sara Tolaney, Dana-Farber Cancer Institute 

PS3-01: 替雷利珠单抗联合sitravatinib和白蛋白结合型紫杉醇治疗未经治的局部复发或转移性三阴性乳腺癌（TNBC）患者：疗效和安全性结果更新

Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer (TNBC): updated efficacy and safety results.

刘西禹 复旦大学附属肿瘤医院

PS3-02: 顺铂/白蛋白结合型紫杉醇/帕博利珠单抗诱导治疗后，帕博利珠单抗±奥拉帕利维持治疗在转移性TNBC患者中的疗效（COMPLEMENT）：一项随机、开放标签、Ⅱ期研究

Induction of Cisplatin/abraxane/pembrolizumab followed by pembrolizumab ± Olaparib Maintenance in triple-negative Metastatic breast cancer patients (COMPLEMENT) – A Randomized, Open-label, Phase II Study.

胡夕春 复旦大学附属肿瘤医院

PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial.

Christian F. Singer,  Medical University of Vienna, Vienna, Austria.

PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine.

Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida

PS3-05: 依沃西单抗联合化疗作为TNBC患者一线治疗的安全性和疗效评估

Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC).

王晓稼 浙江省肿瘤医院

PS3-06: A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer (TNBC).

Tao Sun, Lioning Cancer Hospital & Institute, Shenyang, China

PS3-07: SHR-A1811 as Neoadjuvant Treatment in Patients with HR-Positive, HER2-low Breast Cancer: The first-stage results from an open-label, single-arm, two-stage, phase II clinical trial.

Zhenzhen Liu, Regeneron, Gaithersburg, Maryland

PS3-08: 接受一线PM8002/BNT327联合白蛋白结合型紫杉醇治疗的局部晚期或转移性TNBC患者的中位总生存期（OS）：一项随机、开放标签、Ⅱ期研究

Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated wtih First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study.

吴炅 复旦大学附属肿瘤医院

• 7:30-7:45 Discussant (PS3-01, PS3-02, PS3-03, PS3-04)

乳腺癌中的创新免疫治疗方法

Innovative Immunotherapy Approaches in Breast Cancer

Heather McArthur, UT Southwestern, Dallas, Texas

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS3-05, PS3-06, PS3-07, PS3-08)

靶向性强效药：双特异性抗体、TKIs和ADC在乳腺癌中的作用

Targeted Powerhouses: The Role of Bispecific Antibodies, TKIs and ADCs in Breast Cancer.

Thomas Grinda, Gustave Roussy, Villejuif, France

• 8:15-8:30 Panel Q&A

地点和时间：Stars at Night 3-4，12月11日 7:00 – 8:30 am

主持人：Sherene Loi, Peter Macallum Cancer Centre

PS4-01: Predictor of benefit from dose-dense paclitaxel chemotherapy for patients with hormone receptor-positive HER2-negative breast cancer. A GEICAM/9906 sub-study.

Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

PS4-02: Patient-derived Xenografts (PDX) Allow Deconvolution of Combination Chemotherapy Response.

Jonathan Lei, Baylor College of Medicine, Houston, Texas

PS4-03: Calcium Channel Blockers Enhance Efficacy of TROP2-ADC in Overcoming Resistance in Advanced Triple-Negative Breast Cancer.

Jieer Luo, National Cancer Institute Center for Cancer Research, Bethesda, Maryland

PS4-04: MammaPrint® and BluePrint® predict pathological response to neoadjuvant chemotherapy in patients with HR+HER2- early-stage breast cancer enrolled in FLEX.

Joyce  O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial.

Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

PS4-07: Residual disease after HER2 inhibition is driven by a primary tumor subpopulation expressing an ERBB2-low associated transcriptional program.

Sheheryar Kabraji, Roswell Park Comprehensive Cancer Center, Buffalo, New York

PS4-08: 肿瘤异质性过表达CD155通过免疫微环境调节促进HER2阳性乳腺癌治疗耐药性

The tumor heterogeneous overexpressed CD155 promotes treatment resistance in HER2-positive breast cancer through immune microenvironment modulation.

张怡 复旦大学附属肿瘤医院

PS4-09: Spatial Omics Analysis Uncovers Microenvironmental Remodeling and Immune Dynamics in T-DXd Resistant Metastatic Breast Cancer.

Glori Das, Houston Methodist Neal Cancer Center

PS4-10: TNBC-DX Genomic Test Predicts High pCR in Triple-Negative Breast Cancer with sTILs ≥30% Treated with Neoadjuvant Docetaxel-Carboplatin with/without Pembrolizumab.

Shane Stecklein, University of Kansas Health System, Kansas City, Kansas

• 7:30-7:45 Discussant (PS4-01, PS4-02, PS4-03, PS4-04)

化疗

Chemotherapy

Reshma Mahtani, Miami Cancer Institute, Miami, Florida

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS4-06, PS4-07, PS4-08, PS4-09, PS4-10)

靶向性强效药：双特异性抗体、TKIs和ADC在乳腺癌中的作用

Targeted Powerhouses: The Role of Bispecific Antibodies, TKIs and ADCs in Breast Cancer.

Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

• 8:15-8:30 Panel Q&A

地点和时间： Hemisfair Ballroom 3，12月11日 7:00 – 8:30 am 

主持人：Anne Blaes, Masonic Cancer Center University of Minnesota

PS5-01: The association between pembolizumab and risk of venous thromboembolism in patients with breast cancer.

Cho-Han Chiang, Mount Auburn Hospital, Cambridge, Massachusetts

PS5-02: The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer.

Cho-Han Chiang, Mount Auburn Hospital, Cambridge, Massachusetts

PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study.

Alexis LeVee, City of Hope, Los Angeles, California

PS5-04: Anti-RANKL bone resorptive therapy increases immune-related adverse events (irAE) in breast cancer patients (pts) treated with pembrolizumab.

Alexis LeVee, City of Hope, Los Angeles, California

PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study.

Saya Jacob, Northwestern Medicine-Northwestern Memorial Hospital, Chicago, Illinois

PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)

Andreas Müller, Kantonsspital Winterthur, Winterhur, Switzerland

PS5-07: Financial difficulty over time in young adults with breast cancer.

Sara Myers, Brigham and Women’s Hospital, Boston, Massachusetts

PS5-08: Effects of Cryotherapy on Objective and Subjective Symptoms of Taxane Induced Neuropathy in Patients with Early Breast Cancer: A National, Multicenter, Prospective, Randomized, Controlled Trial.

Maria Elisabeth Lendorf, Nordjaellands Hospital, Capital Region, Denmark

PS5-09: Feasibility of an Interactive Care Plan for Self-Management of Toxicity Symptoms and Surveillance for Non-Metastatic Disease in Breast Cancer Survivors.

Daniela Stan, Mayo Clinic, Rochester, Minnesota

• 7:30-7:45 Discussant (PS5-01, PS5-02, PS5-03, PS5-04, PS5-05)

免疫治疗与不良反应

Immunotherapy and adverse effects

Sarah Sammans, Dana-Farber Cancer Institute, Boston, Massachusetts

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS5-06, PS5-07, PS5-08, PS5-09)

可见与不可见的毒性：改善结果

Seen and Unseen Toxicities: Improving outcomes

Marcela Mazo Canola, UT Health Mays Cancer Center, San Antonio, Texas

• 8:15-8:30 Panel Q&A

地点和时间：Hemisfair Ballroom 1-2，12月11日 7:00 – 8:30 am

主持人：Shom Goel, Peter MacCallum Cancer Centre

PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial.

Cristina Saura, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients.

Dejan Juric, Mass General Research Institute Cancer Center, Boston, Massachusetts

PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study.

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia.

Kerstein Sinkevicius, BioBridge Oncology Therapeutics, Palo Alto, California

PS7-05: Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).

Maxwell Lloyd, Beth Israel Deaconess Medical Center, Boston, Massachusetts

PS7-06: Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase 1b/2, open-label, umbrella study.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC).

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS7-08: Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer.

Richard Baird, University of Cambridge, Cambridge, United Kingdom

• 7:30-7:45 Discussant (PS7-01, PS7-02, PS7-03, PS7-04)

PI3K抑制剂

PI3K Inhibitors

Chris Vaklavas, Huntsman Cancer Institute, Salt Lake City, Utah

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS7-05, PS7-06, PS7-07, PS7-08)

选择性雌激素受体降解剂（SERD）

SERD

Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

• 8:15-8:30 Panel Q&A

时间：12月11日 8:30 – 8:35 am

联合主席：Carlos Arteaga, MD, UT Southwestern Medical Center, Dallas, Texas

Virginia Kaklamani, MD, UT Health Mays Cancer Center, San Antonio, Texas

时间：12月11日 8:35 – 9:15 am

药物控制癌症的新原则

(Re)emerging Principles for Controlling Cancer with Drugs

William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts

地点和时间：Hall 1，12月11日 9:15 – 11:30 am

主持人：Alexandra Thomas, Duke Cancer Institute, Durham, North Carolina, and Reshma Mahtani, Miami Cancer Institute, Miami, Florida

GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

GS1-02: Discussant about Ember 3

Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts 

GS1-03: Ⅲ期PHILA试验：吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗未经治的HER2阳性转移性乳腺癌患者的无进展生存期（PFS）的预设最终分析

Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial.

徐兵河 中国医学科学院肿瘤医院

GS1-04: HER2靶向抗体偶联药物（ADC）SHR-A1811在HER2阳性早期乳腺癌新辅助治疗中的研究：一项前瞻性、随机、开放标签、Ⅱ期试验

HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial.

李俊杰 复旦大学附属肿瘤医院

GS1-05: Discussant about GS1-03, 04, and 05

Aleix Prat, Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain

GS1-06: PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.

Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin

GS1-07: Discussant about GS1-06

Gabrielle Rocque, University of Alabama at Birmingham, Birmingham, Alabama

GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.

Matteo Lambertini, University of Genova, Genova, Italy

GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.

Judy Garber, Dana-Farber Cancer Institute, Boston, Massachusetts

时间：12月11日 11:30 am – 12:00 pm

奖项由德克萨斯州达拉斯市德克萨斯大学西南医学中心的Carlos Arteaga颁发

Award presented by Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

Laura J. van 't Veer, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

地点和时间：Hall 1，12月11日 12:00– 12:50 pm

主持人：Shom Goel, University of Melbourne Peter MacCallum Cancer Centre

RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).

Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts

RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy

RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).

Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands

RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer.

Azka Ali, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois

RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.

Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois

RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.

Katie Johansen Taber, Myriad Genetics, San Francisco, California

RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.

Polly Niravath, Dr. Mary and Ron Neal Cancer Center, Houston, Texas

地点和时间：Halls 2-3，12月11日 12:30 – 2:00 pm

地点和时间：Stars at Night 3-4，12月11日 12:00 – 1:45 pm

主持人：Ismail Jatoi, UT Health Mays Cancer Center, San Antonio, Texas

基于风险的人群筛查

Risk-Based Screening in the Average Population

Karla Kerlikowske, University of California San Francisco, San Francisco, California

新型成像模式

Novel Imaging Modalities

Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts

高危妇女筛查：临床视角

Screening for High-Risk Women: The Clinical Perspective

Seema Khan, Northwestern University Feinberg School of Medicine, Chicago, Illinois

• Panel Discussion

地点和时间：Stars at Night 1-2，12月11日 1:00 – 1:50 pm

主持人：Debra Patt, Texas Oncology, Austin, Texas

Patient Advocate: Kelly Shanahan, Tahoe, California

Sonya Reid, Vanderbilt Ingram Cancer Center, Nashville, Tennessee

Icro Meattini, Florence University Hospital, Florence, Italy

Tari King, Dana-Farber Cancer Institute, Boston, Massachusetts

Joannie Ivory, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Anne Salomon, Institut Curie, Paris, France

Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts

地点和时间：Room 221ABC，12月11日 1:00 – 3:30 pm

主持人：Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts 

为成功奠定基础

Setting the stage for Success

Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts 

解决女性研究人员面临的系统性障碍的循证策略

Evidence-based strategies to address systemic barriers facing women researchers

Reshma Jagsi, Emory University, Atlanta, Georgia

地点和时间：Stars at Night 3-4，12月11日 2:00 – 3:00 pm

主持人：Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

TILs：十年研究后的更新

TILs: An Update After 10 Years of Research

Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

TILs之外的免疫生物标志物

Immune Biomarkers Beyond TILs 

Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

免疫生物标志物在临床试验中的应用

Deploying Immune Biomarkers in Clinical Trials

Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas

• Panel Discussion

地点和时间：Stars at Night 1-2，12月11日 2:00 – 3:00 pm

主持人：Antonio Wolff, Johns Hopkins University, Baltimore, Maryland

如何定义三阴性乳腺癌

How to Define Triple Negative Breast Cancer

Rebecca Dent, National Cancer Center Singapore, Singapore
Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

肿瘤特异性药物开发

Tumor Agnostic Drug Development

Funda Meric, MD Anderson Cancer Center, Houston, Texas
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

地点和时间：Stars at Night 1-2，12月11日 3:00 – 3:30 pm

主持人：Sofia Merajver, University of Michigan Health Rogel Cancer Center, Ann Arbor, Michigan

获奖人：Christina Curtis, Stanford University School of Medicine, Palo Alto, California

地点和时间：Hemisfair Ballroom 3，12月11日 3:30 – 5:15 pm

主持人：Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

蛋白水解靶向嵌合体（PROTACs）

PROTACs

Stephen Hinshaw, Stanford Cancer Institute, Palo Alto, California

溶酶体靶向嵌合体

Lysosome-targeting Chimeras

Weiping Tang, Tang Research Group, Univerisity of Wisconsin School of Pharmacy, Madison, Wisconsin

双特异性抗体

Biparatropic Antibodies

Saireudee Chaturantabut, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

SERDs的最新研究进展

Latest on selective estrogen receptor degraders (SERDs)

Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

• Panel Discussion

地点和时间：Stars at Night 1-2，12月11日 3:30 – 5:15 pm

主持人：William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois, and Sara Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington

病例介绍和讨论者

Case Presentations and Discussants:

Michael Oliphant, Harvard Medical School, Boston, Massachusetts
Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California
Neil Vasan, Columbia University Irving Medical Center, New York, New York
Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Amy Beumer, Patient Advocate, Mason, Ohi

病例1：新诊断的ER+HER2-MBC：基因组学考量

Case 1: New diagnosis ER+HER2-MBC: genomic considerations

病例2：我们能否将CDK4/6抑制剂治疗推迟至二线？

Case 2: Can we delay CDK4/6i treatment until the second line?

病例3：在CDK4/6抑制剂治疗进展后，如何选择具有PI3K通路突变患者的治疗方案

Case 3: Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations

病例4：如何选择肿瘤ESR1突变患者的治疗方案

Case 4: Selecting treatment for patient with tumor ESR1 mutation

病例5：何时从内分泌治疗转向化疗或ADC？

Case 5: When it's time to move on from endocrine approaches, chemo or ADC?

地点和时间：Hemisfair Ballroom 1-2，12月11日 3:30 – 5:15 pm

主持人：Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

ABC的ADCs：历史、作用机制、耐药机制

The ABC of ADCs: history, mechanism of action, mechanisms of resistance

John Lambert, John Lambert Consulting, Cambridge, Massachusetts

使用ADCs治疗乳腺癌：临床角色和新兴挑战

Treating breast cancer with ADCs: clinical role and emerging challenge.

Giuseppe Curigliano, European Institute of Oncology, Milan, Italy

开发ADCs的艺术：学术界和工业界交叉点的见解

The art of developing ADCs: insights at the intersection of academia and industry.

Ingrid Mayer, AstraZeneca, Frederick, Maryland

瞄准靶标：通过新型生物标志物和创新分子结构提高ADCs的精确度

Aiming for the target: Increasing the precision of ADCs through novel biomarkers and innovative molecular constructs.

Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

地点和时间：Stars at Night 3-4，12月11日 3:30 – 5:15 pm

主持人：Tari King, Dana-Farber Brigham Cancer Center, Boston, Massachusetts

Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania

淋巴水肿的外科预防与管理

Surgical Prevention and Management of Lymphedema

Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida

腋窝管理：何时进行解剖和放射治疗

Axillary Management: When to Dissect and When to Radiate

Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada

让我们谈谈PBI

Let’s Talk About PBI

Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

• Panel Discussion

地点和时间：Halls 2-3，12月11日 5:30 – 7:00 pm

详细日程见链接https://rs-os-lyh-dt-publicread-file-bosmetadata-prod.liangyihui.net/boss-upload/Pk2oYdrR4WV1r_x1EKnesQ/vWrbqBwXMITnzkIS.pdf2024

SABCS | 新鲜出炉！哪些乳腺癌研究成果值得关注？

2024 SABCS会议预告｜12月10日有哪些精彩看点？

本文整理自SABCS官网公布的信息，不代表名单为实际现场参会专家。若有任何遗漏或错误，可联系我们进行修改。